Phenotype in Candida albicans of a disruption of the BGL2 gene encoding a 1,3-beta-glucosyltransferase.
The BGL2 gene encodes a unique 1,3-beta-glucosyltransferase (Bgl2p) present in the cell wall of Candida albicans and other fungi. Although believed to be involved in cell wall assembly, disruption of the gene in saccharomyces cerevisiae showed no apparent phenotype. We performed sequential disruptions of the BGL2 loci in a homozygous ura3 clinical isolate of C. albicans using the URA3 blaster method, in order to investigate the role of Bgl2p in this dimorphic, pathogenic fungus. Strain CACW-1 contained disruptions of both homologues of the BGL2 gene and lacked Bgl2p, as assessed by protein extraction, SDS-PAGE and Western blot analysis, and enzyme assay; however, residual non-Bgl2p transferase activity was detected. CACW-1 was attenuated in virulence for mice when compared to an isogenic parent strain, and fewer organisms were recovered from the kidneys of infected animals. Additional phenotypic changes included: (1) a dramatic increase in the sensitivity to the chitin synthesis inhibitor nikkomycin Z when CACW-1 cells were incubated at 37 or 42 degrees C; (2) an 8.7 +/- 1.6% slower growth rate at 37 degrees C for CACW-1 when compared to its isogenic parent; and (3) aggregation of CACW-1 cells during stationary phase and/or incubation of stationary phase cells in phosphate buffer. Characterization of SDS-extracted cell walls did not reveal any significant differences in the levels of 1,3-beta- or 1,6-beta-glucan. These data reveal that loss of Bgl2p does have a phenotype in C. albicans, and indicate that (1) loss of Bgl2p function renders cells more dependent on chitin for wall integrity, and attenuates virulence (probably due to subtle changes in wall structure), and (2) that additional 1,3-beta-glucosyltransferases are present in the C. albicans BGL2 disruptant.
Sarthy
Aparna V
AV
Anti-infective Research Division, D47M/AP9A, 100 Abbott Park Road, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
McGonigal
Thomas
T
Anti-infective Research Division, D47M/AP9A, 100 Abbott Park Road, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
Coen
Michael
M
Anti-infective Research Division, D47M/AP9A, 100 Abbott Park Road, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
Frost
David J
DJ
Anti-infective Research Division, D47M/AP9A, 100 Abbott Park Road, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
Meulbroek
Jonathan A
JA
Anti-infective Research Division, D47M/AP9A, 100 Abbott Park Road, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
Goldman
Robert C
RC
Anti-infective Research Division, D47M/AP9A, 100 Abbott Park Road, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology; D002176:Candida albicans / Q000201:enzymology / Q000235:genetics* / Q000472:pathogenicity; D002177:Candidiasis; D002473:Cell Wall / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure; D005656:Fungal Proteins / Q000235:genetics*; D005800:Genes, Fungal; D004693:Glucan Endo-1,3-beta-D-Glucosidase / Q000235:genetics*; D005936:Glucans / Q000737:chemistry; D005964:Glucosyltransferases / Q000235:genetics*; D006031:Glycosylation; D007668:Kidney / Q000382:microbiology; D051379:Mice; D008826:Microbial Sensitivity Tests; D016296:Mutagenesis; D010641:Phenotype; D014774:Virulence / Q000235:genetics
D000935:Antifungal Agents; D005656:Fungal Proteins; D005936:Glucans; D005964:Glucosyltransferases; D004693:Glucan Endo-1,3-beta-D-Glucosidase